-
1
-
-
0027213870
-
Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia
-
Estey E, Plunkett W, Gandhi V, Rios M, Kantarjian H, Keating M. Fludarabine and arabinosylcytosine therapy for refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993; 9:343-50.
-
(1993)
Leuk Lymphoma
, vol.9
, pp. 343-350
-
-
Estey, E.1
Plunkett, W.2
Gandhi, V.3
Rios, M.4
Kantarjian, H.5
Keating, M.6
-
2
-
-
85087577492
-
Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid and /or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed acute myeloid leukaemia and myelodysplastic syndrome
-
Estay EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin + all-trans retinoic acid and /or granulocyte-colony stimulating factor in poor prognosis newly-diagnosed acute myeloid leukaemia and myelodysplastic syndrome. Blood 1999; 93:278-84.
-
(1999)
Blood
, vol.93
, pp. 278-284
-
-
Estay, E.H.1
Thall, P.F.2
Pierce, S.3
Cortes, J.4
Beran, M.5
Kantarjian, H.6
-
3
-
-
0028344644
-
Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes; comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor
-
Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes; comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994; 12:671-8.
-
(1994)
J Clin Oncol
, vol.12
, pp. 671-678
-
-
Estey, E.1
Thall, P.2
Andreeff, M.3
Beran, M.4
Kantarjian, H.5
O'Brien, S.6
-
4
-
-
0028104171
-
FLAG (fludarabine + high-dose cytarabine + G-CSF): An effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias
-
Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, et al. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. Leukemia 1994; 8:1842-6.
-
(1994)
Leukemia
, vol.8
, pp. 1842-1846
-
-
Visani, G.1
Tosi, P.2
Zinzani, P.L.3
Manfroi, S.4
Ottaviani, E.5
Testoni, N.6
-
5
-
-
0030326145
-
High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia
-
Clavio M, Carrara P, Miglino M, Pierri I, Canepa L, Balleari E, et al. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996; 81:513-20.
-
(1996)
Haematologica
, vol.81
, pp. 513-520
-
-
Clavio, M.1
Carrara, P.2
Miglino, M.3
Pierri, I.4
Canepa, L.5
Balleari, E.6
-
6
-
-
6844237007
-
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia
-
Parker JE, Paglivca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 1997; 99:939-44.
-
(1997)
Br J Haematol
, vol.99
, pp. 939-944
-
-
Parker, J.E.1
Paglivca, A.2
Mijovic, A.3
Cullis, J.O.4
Czepulkowski, B.5
Rassam, S.M.6
-
7
-
-
0032439389
-
FLAG-idaraubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission
-
Deane M, Koh M, Foroni I, Galactowicz G, Hoffbrand AV, Lawler M, et al. FLAG-idaraubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Bone Marrow Transplantation 1998; 22: 1137-43.
-
(1998)
Bone Marrow Transplantation
, vol.22
, pp. 1137-1143
-
-
Deane, M.1
Koh, M.2
Foroni, I.3
Galactowicz, G.4
Hoffbrand, A.V.5
Lawler, M.6
-
8
-
-
0031812317
-
IDA-Flag (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission - induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: Experiences of a Phase- II trial
-
Fleischhack G, Hasan C, Graf N, Mann G, Bode U. IDA-Flag (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission - induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a Phase- II trial. Br J Haematol 1998; 102:647-55.
-
(1998)
Br J Haematol
, vol.102
, pp. 647-655
-
-
Fleischhack, G.1
Hasan, C.2
Graf, N.3
Mann, G.4
Bode, U.5
-
9
-
-
0033571328
-
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes
-
Ferrara F, Leoni F, Pinto A, Mirto S, Morra E, Zagonel V, et al. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes. Cancer 1999; 86:2006-13.
-
(1999)
Cancer
, vol.86
, pp. 2006-2013
-
-
Ferrara, F.1
Leoni, F.2
Pinto, A.3
Mirto, S.4
Morra, E.5
Zagonel, V.6
-
10
-
-
0032836387
-
Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML
-
Steinmetz HT, Schulz A, Staib P, Scheid C, Glasmacher A, Neufang A, et al. Phase-II trial of idarubicin, fludarabine, cytosine arabinoside, and filgrastim (Ida-FLAG) for treatment of refractory, relapsed and secondary AML. Ann Haematol 1999; 78:418-25.
-
(1999)
Ann Haematol
, vol.78
, pp. 418-425
-
-
Steinmetz, H.T.1
Schulz, A.2
Staib, P.3
Scheid, C.4
Glasmacher, A.5
Neufang, A.6
-
11
-
-
0023854422
-
Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells
-
Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48:329-34.
-
(1988)
Cancer Res
, vol.48
, pp. 329-334
-
-
Gandhi, V.1
Plunkett, W.2
-
12
-
-
0027450455
-
Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy
-
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11:116-24.
-
(1993)
J Clin Oncol
, vol.11
, pp. 116-124
-
-
Gandhi, V.1
Estey, E.2
Keating, M.J.3
Plunkett, W.4
-
13
-
-
0025643306
-
Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro
-
Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4:826-34.
-
(1990)
Leukemia
, vol.4
, pp. 826-834
-
-
Tafuri, A.1
Andreeff, M.2
-
14
-
-
0028568321
-
Fludarabine+Ara-C +G-CSF: Cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells
-
Tosi P, Visani G, Ottaviani E, Manfroi S, Zinzani PI, Tura S. Fludarabine+Ara-C +G-CSF: cytotoxic effect and induction of apoptosis on fresh acute myeloid leukemia cells. Leukemia 1994; 8:2076-82.
-
(1994)
Leukemia
, vol.8
, pp. 2076-2082
-
-
Tosi, P.1
Visani, G.2
Ottaviani, E.3
Manfroi, S.4
Zinzani, P.I.5
Tura, S.6
-
15
-
-
0031005627
-
Acute myeloid keukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group Study
-
Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovac ML, Chen IM, et al. Acute myeloid keukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: a Southwest Oncology Group Study. Blood 1997; 89:3323-9.
-
(1997)
Blood
, vol.89
, pp. 3323-3329
-
-
Leith, C.P.1
Kopecky, K.J.2
Godwin, J.3
McConnell, T.4
Slovac, M.L.5
Chen, I.M.6
-
16
-
-
0025915728
-
Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission
-
Horowitz MM, Messerer D, Hoelzer D. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991; 115:13-18.
-
(1991)
Ann Intern Med
, vol.115
, pp. 13-18
-
-
Horowitz, M.M.1
Messerer, D.2
Hoelzer, D.3
-
17
-
-
0026754295
-
Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy
-
Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W, et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80:1090-3.
-
(1992)
Blood
, vol.80
, pp. 1090-1093
-
-
Biggs, J.C.1
Horowitz, M.M.2
Gale, R.P.3
Ash, R.C.4
Atkinson, K.5
Helbig, W.6
-
18
-
-
0036244526
-
Acute myeloid leukemia: Treatment of adults under 60 years
-
Burnett AK. Acute myeloid leukemia: treatment of adults under 60 years. Rev Clin Exp Hematol 2002; 6:26-45.
-
(2002)
Rev Clin Exp Hematol
, vol.6
, pp. 26-45
-
-
Burnett, A.K.1
-
19
-
-
0346433669
-
Fludarabine cytosine arabinoside, granulocyte colony factor with or with out idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes
-
Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, et al. Fludarabine cytosine arabinoside, granulocyte colony factor with or with out idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 2004; 124:26-32.
-
(2004)
Br J Haematol
, vol.124
, pp. 26-32
-
-
Virchis, A.1
Koh, M.2
Rankin, P.3
Mehta, A.4
Potter, M.5
Hoffbrand, A.V.6
-
20
-
-
0038180704
-
FLAG-Ida in the treatment of refractory/relapsed acute myeloid leukemia: Single - Centre experience
-
Pastore D, Specchia G, Carluccio P, Liso A, Mestice A, Rizzi R, et al. FLAG-Ida in the treatment of refractory/relapsed acute myeloid leukemia: single - centre experience. Ann Hematol 2003; 82:231-5.
-
(2003)
Ann Hematol
, vol.82
, pp. 231-235
-
-
Pastore, D.1
Specchia, G.2
Carluccio, P.3
Liso, A.4
Mestice, A.5
Rizzi, R.6
-
21
-
-
0036994363
-
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients
-
Clavio M, Gatto S, Beltrami G, Quintino S, Canepa L, Pierri I, et al. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasible and effective therapeutic strategy for de novo AML patients. J Exp Clin Cancer Res 2002; 21:482-7.
-
(2002)
J Exp Clin Cancer Res
, vol.21
, pp. 482-487
-
-
Clavio, M.1
Gatto, S.2
Beltrami, G.3
Quintino, S.4
Canepa, L.5
Pierri, I.6
-
22
-
-
0035035504
-
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia
-
Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pieri I, et al. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia. Leuk Lymphoma 2001; 40:305-13.
-
(2001)
Leuk Lymphoma
, vol.40
, pp. 305-313
-
-
Clavio, M.1
Gatto, S.2
Beltrami, G.3
Cerri, R.4
Carrara, P.5
Pieri, I.6
-
23
-
-
10744230708
-
A feasibility study of simultaneous administration of gemtozumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
-
Kell WJ, Burnett AK, Chopra R, Yin JAL, Clark RE, Rohatiner A et al. A feasibility study of simultaneous administration of gemtozumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia Blood 2003; 102:4277-83.
-
(2003)
Blood
, vol.102
, pp. 4277-4283
-
-
Kell, W.J.1
Burnett, A.K.2
Chopra, R.3
Yin, J.A.L.4
Clark, R.E.5
Rohatiner, A.6
-
24
-
-
0033761793
-
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
-
Yalman N, Sarper N, Devecioglu O, Anak S, Eryilmaz E, Can M, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia. Turk J Pediatr 2000; 42:198-204.
-
(2000)
Turk J Pediatr
, vol.42
, pp. 198-204
-
-
Yalman, N.1
Sarper, N.2
Devecioglu, O.3
Anak, S.4
Eryilmaz, E.5
Can, M.6
-
25
-
-
0033017902
-
Early allogeneic transplantation for refractory and relapsed acute leukemia following remission induction with FLAG
-
Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D, et al. Early allogeneic transplantation for refractory and relapsed acute leukemia following remission induction with FLAG. Leukemia 1999; 13:786-91.
-
(1999)
Leukemia
, vol.13
, pp. 786-791
-
-
Byrne, J.L.1
Dasgupta, E.2
Pallis, M.3
Turzanski, J.4
Forman, K.5
Mitchell, D.6
|